GlassScriptPhysician profile
Lawrence Tawiah
NPI 1508223108
$2,524.94
in general payments reported to CMS, 2019-2025
21 companies · $958 in 2025
The $958 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.48 · 2022: $326 · 2023: $492 · 2024: $649 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,099.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,098.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $458.49 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $424.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $335.47 | 2021-2025 | Mounjaro, Zepbound, Kisunla |
| Pfizer INC. | $163.78 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $153.33 | 2022-2025 | Trintellix |
| Sumitomo Pharma America, INC. | $139.49 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $126.32 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $105.53 | 2022-2025 | Airsupra, Breztri, Fasenra |
| Abbvie INC. | $95.00 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.54 | 2022-2025 | Jardiance, Tradjenta |
| Dexcom, INC. | $86.43 | 2023-2025 | Dexcom G6 Transmitter |
| E.R. Squibb & Sons, L.L.C. | $59.68 | 2022-2025 | Eliquis, Camzyos |
| Exact Sciences Corporation | $56.83 | 2024-2025 | Cologuard Collection Kit |
| Merck Sharp & Dohme LLC | $47.59 | 2022-2023 | Verquvo, Belsomra, Lagevrio |
| Janssen Pharmaceuticals, INC | $45.84 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $32.54 | 2025 | Trelegy Ellipta, Arexvy |
| Boston Scientific Corporation | $27.33 | 2025 | Ams 700 |
| Astellas Pharma US INC | $23.03 | 2023 | Veozah |
| Kowa Pharmaceuticals America, INC. | $20.37 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $15.63 | 2024 | |
| Soleno Therapeutics, INC. | $14.81 | 2025 | Vykat Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Tawiah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.